Quantcast

Latest Genentech Stories

2014-05-07 12:26:55

Roche/Genentech's Avastin Continues to Garner the Greatest Physician-Reported Patient Share in DME Due to Its Low Relative Cost, According to Findings from Decision Resources Group BURLINGTON, Mass., May 7, 2014 /PRNewswire/ -- Decision Resources Group finds that, ahead of the anticipated label expansion of Regeneron's Eylea for diabetic macular edema (DME) in August 2014, over half of surveyed U.S. retinal specialists and general ophthalmologists currently prescribe this anti-vascular...

2014-05-07 12:26:20

Ultimate Award Recipient Rackspace and Finalists including Cisco, ConAgra Foods, Genentech and Tata Consultancy Services focus on programs to acquire, grow and retain employees, manage change, and transform human resource decision-making FORT LAUDERDALE, Fla., May 7, 2014 /PRNewswire/ -- Bersin by Deloitte, a leading research and advisory firm empowering Human Resource (HR) organizations to drive bottom-line impact, today announced Rackspace® Hosting, a global leader in hybrid cloud...

2014-05-06 08:36:41

--PDL's Revolutionary Antibody Technology Provided Basis for Eight Successful Drugs Currently on the Market-- INCLINE VILLAGE, Nev., May 6, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that two inventors of the company's patented breakthrough antibody technology have been named as a top-three finalist for the European Patent Office's highly prestigious 2014 European Inventor Award in the "Non-European Countries" category. The award, which is...

2014-05-01 12:28:46

Reduction in Exacerbations Remains the Top Driver of Physician Prescribing Choice in Moderate to Severe Asthma, According to Findings from Decision Resources Group BURLINGTON, Mass., May 1, 2014 /PRNewswire/ -- Decision Resources Group finds that 90 percent of surveyed U.S. payers indicated a willingness to pay a premium-price for a novel therapy with substantially greater improvements in reducing exacerbations than Genentech/Novartis's Xolair in the treatment of severe asthma. Surveyed U.S....

2014-04-10 12:26:46

Improved Overall Survival and Delayed Disease Progression are the Greatest Unmet Needs in this Population, According to Findings from Decision Resources Group BURLINGTON, Mass., April 10, 2014 /PRNewswire/ -- Decision Resources Group finds that interviewed oncologists are optimistic that emerging targeted therapies will offer efficacy advantages over current treatment options for metastatic gastric cancer. Physicians anticipate that Roche/Genentech/Chugai's Perjeta and...

2014-04-02 12:32:34

NEW YORK, April 2, 2014 /PRNewswire-iReach/ -- A mobile application focusing on rheumatoid arthritis management -- created by DKBmed, LLC, in collaboration with Clifton O. Bingham III, MD, Director of the Johns Hopkins Arthritis Center and the Johns Hopkins University School of Medicine -- was ranked #1 in 2013 by rheumatologists on the Rheumatology Network website and highly rated in 2014 on the Healthline website. Called Rheumatoid Arthritis Vital Education (RAVE) Mobile, the app was...

2014-03-27 12:31:03

LONDON, March 27, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Global and China Monoclonal Antibody Industry Report, 2013-2017 Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of...

2014-03-27 12:30:38

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/rwdz5w/therapy_class ) has announced the addition of the "Therapy Class Overview: Rituximab biosimilar" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson's Remicade,...

2014-03-26 08:28:26

VANCOUVER, British Columbia, March 26, 2014 /PRNewswire/ -- Xenon Pharmaceuticals Inc. today announced the establishment of a new collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for pain genetics, with the goal of discovering and validating new therapeutic targets and mechanisms for treating pain. The collaboration leverages Xenon's Extreme Genetics discovery platform to focus on rare phenotypes where individuals have an inability to perceive...

2014-03-25 20:22:11

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/q29sqz/global_and ) has announced the addition of the "Global and Chinese Monoclonal Antibody Industry Report" [http://www.researchandmarkets.com/research/q29sqz/global_and ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Currently, monoclonal antibody agents have been successfully used in the treatment...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related